Advertisement

Molecular Biology Reports

, Volume 45, Issue 6, pp 1611–1619 | Cite as

Neuregulin-1β modulates myogenesis in septic mouse serum-treated C2C12 myotubes in vitro through PPARγ/NF-κB signaling

  • Li Liu
  • Xueru Liu
  • Yiping Bai
  • Ni Tang
  • Jie Li
  • Yingying Zhang
  • Jiali Wu
  • Xiaobin Wang
  • Jicheng WeiEmail author
Original Article
  • 176 Downloads

Abstract

Sepsis-induced skeletal muscle atrophy is a pathological condition characterized by the loss of strength and muscle mass. Cytokine-induced apoptosis and impaired myogenesis play key roles in the development of this condition. However, the complete underlying mechanism remains largely unknown. Neuregulins are glial growth factors essential for myogenesis that regulate muscle metabolism. We investigated the role of neuregulin-1β (NRG-1β) in sepsis-induced apoptosis and myogenesis in skeletal muscle using a serum-based in vitro sepsis model. C2C12 myoblasts were differentiated by treatment with proliferative medium for 7 days. Then, cells were treated with 2% sham mouse serum, 1 nM NRG-1β in 2% sham mouse serum, 2% septic mouse serum (SMS), or 1 nM NRG-1β in 2% SMS. Exposure to SMS induced apoptosis, impaired myogenesis, and downregulated PPARγ. NRG-1β co-incubation remedied all these effects and inhibited NF-κB transcriptional activity. A specific PPARγ antagonist (GW9662) was also administered as a 2-h pretreatment to block PPARγ-mediated signaling and appeared to attenuate the effects of NRG-1β. Taken together, our results demonstrate that NRG-1β functions via a PPARγ/NF-κB-dependent pathway to modulate myogenesis and protect against apoptosis in SMS-treated C2C12 myotubes.

Keywords

Neuregulin-1 Muscular atrophy Sepsis Apoptosis PPAR gamma NF-kappa B 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China [Grant Number 81401632]. The funding source has no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving Human Participants and/or Animals

All experimental procedures involving animals were approved by the Animal Ethics and Use Committee of Southwest Medical University. Male and female C57BL/6 mice were obtained from the Experimental Animal Centre of Southwest Medical University (Luzhou, China) and received humane care according to the Care and Use Committee of Southwest Medical University.

Informed consent

Not applicable.

Supplementary material

11033_2018_4293_MOESM1_ESM.docx (399 kb)
Supplementary material 1 (DOCX 399 KB)

References

  1. 1.
    Nardelli P, Vincent JA, Powers R (2016) Reduced motor neuron excitability is an important contributor to weakness in a rat model of sepsis. Exp Neurol 282:1–8.  https://doi.org/10.1016/j.expneurol.2016.04.020 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nardi O, Zavala E, Martin C, Nanas S, Scheeren T, Polito A, Borrat X, Annane D (2018) Targeting skeletal muscle tissue oxygenation (StO2) in adults with severe sepsis and septic shock: a randomised controlled trial (OTO-StS Study). BMJ Open 19 8(3):e017581.  https://doi.org/10.1136/bmjopen-2017-017581 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Liu L, Xie F, Wei K, Hao XC, Li P, Cao J, Min S (2016) Sepsis induced denervation-like changes at the neuromuscular junction. J Surg Res 200(2):523–532.  https://doi.org/10.1016/j.jss.2015.09.012 CrossRefPubMedGoogle Scholar
  4. 4.
    Rossaint J, Zarbock A (2015) Pathogenesis of multiple organ failure in sepsis. Crit Rev Immunol 35(4):277–291CrossRefGoogle Scholar
  5. 5.
    Latronico N, Fenzi F, Recupero D et al (1996) Critical illness myopathy and neuropathy. Lancet 347:1579–1582CrossRefGoogle Scholar
  6. 6.
    Hund E (2001) Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248:929–934CrossRefGoogle Scholar
  7. 7.
    Garnacho-Montero J, Amaya-Villar R, García-Garmendía JL, Madrazo-Osuna J, Ortiz-Leyba C (2005) Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 33:349–354CrossRefGoogle Scholar
  8. 8.
    Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL et al (2001) Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 27:1288–1296CrossRefGoogle Scholar
  9. 9.
    Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE (2009) IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 20:604–612.  https://doi.org/10.1681/ASN.2008060628 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Williams A, Wang JJ, Wang L, Sun X, Fischer JE, Hasselgren PO (1998) Sepsis in mice stimulates muscle proteolysis in the absence of IL-6. Am J Physiol 275:R1983–R1991PubMedGoogle Scholar
  11. 11.
    Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269–272. doi: 10.1186%2Frr67CrossRefGoogle Scholar
  12. 12.
    Haddad F, Zaldivar F, Cooper DM, Adams GR (2005) IL-6-induced skeletal muscle atrophy. J Appl Physiol 98:911–917.  https://doi.org/10.1152/japplphysiol.01026.2004 CrossRefPubMedGoogle Scholar
  13. 13.
    Zhao Q, Yang ST, Wang JJ et al (2015) TNF alpha inhibits myogenic differentiation of C2C12 cells through NF-κB activation and impairment of IGF-1 signaling pathway. Biochem Biophys Res Commun 458:790–795.  https://doi.org/10.1016/j.bbrc.2015.02.026 CrossRefPubMedGoogle Scholar
  14. 14.
    Magee P, Pearson S, Whittingham-Dowd J, Allen J (2012) PPARγ as a molecular target of EPA anti-inflammatory activity during TNF-α-impaired skeletal muscle cell differentiation. J Nutr Biochem 23:1440–1448.  https://doi.org/10.1016/j.jnutbio.2011.09.005 CrossRefPubMedGoogle Scholar
  15. 15.
    Kim D, Chi S, Lee KH et al (1999) Neuregulin stimulates myogenic differentiation in an autocrine manner. J Biol Chem 274:15395–15400.  https://doi.org/10.1074/jbc.274.22.15395 CrossRefPubMedGoogle Scholar
  16. 16.
    Simmons LJ, Surles-Zeigler MC, Li Y, Ford GD, Newman GD, Ford BD (2016) Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway. J Neuroinf 13: 237.CrossRefGoogle Scholar
  17. 17.
    Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA (2009) Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4:31–36.  https://doi.org/10.1038/nprot.2008.214 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kislinger T, Gramolini AO, Pan Y, Rahman K, MacLennan DH, Emili A (2005) Proteome dynamics during C2C12 myoblast differentiation. Mol Cell Proteom 4:887–901.  https://doi.org/10.1074/mcp.M400182-MCP200 CrossRefGoogle Scholar
  19. 19.
    Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, Rutkowski JL (2001) Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci 17:761–767.  https://doi.org/10.1006/mcne.2000.0967 CrossRefPubMedGoogle Scholar
  20. 20.
    Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001) Inflammatory cytokines inhibit myogenic differentation through activation of nuclear factor-kappaB. FASEB J 15:1169–1180CrossRefGoogle Scholar
  21. 21.
    Li YP, Reid MB (2000) NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 279:R1165–R1170.  https://doi.org/10.1152/ajpregu.2000.279.4.R1165 CrossRefPubMedGoogle Scholar
  22. 22.
    Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M (2005) Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 111:996–1005.  https://doi.org/10.1161/01.CIR.0000156469.96135.0D CrossRefPubMedGoogle Scholar
  23. 23.
    Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA (2011) STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 6:e22538.  https://doi.org/10.1371/journal.pone.0022538 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Adams V, Mangner N, Gasch A et al (2008) Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol 384:48–59.  https://doi.org/10.1016/j.jmb.2008.08.087 CrossRefPubMedGoogle Scholar
  25. 25.
    Goodman MN (1994) Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205:182–185CrossRefGoogle Scholar
  26. 26.
    Fukazawa R, Miller TA, Kuramochi Y et al (2003) Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 35:1473–1479CrossRefGoogle Scholar
  27. 27.
    Flores AI, Mallon BS, Matsui T, Ogawa W, Rosenzweig A, Okamoto T, Macklin WB (2000) Akt-mediated survival of oligodendrocytes induced by neuregulins. J Neurosci 20:7622–7630CrossRefGoogle Scholar
  28. 28.
    Lai KO, Ip FC, Cheung J et al (2001) Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction. Mol Cell Neurosci 17:1034 – 1047.  https://doi.org/10.1006/mcne.2001.0997 CrossRefPubMedGoogle Scholar
  29. 29.
    Lebrasseur NK, Cote GM, Miller TA et al (2003) Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol 284:C1149 –1155.  https://doi.org/10.1152/ajpcell.00487.2002 CrossRefPubMedGoogle Scholar
  30. 30.
    Suarez E, Bach D, Cadefau J et al (2001) novel role of neuregulin in skeletal muscle Neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. J Biol Chem 276:18257–18264.  https://doi.org/10.1074/jbc.M008100200 CrossRefPubMedGoogle Scholar
  31. 31.
    Jo SA, Zhu X, Marchionni MA et al (1995) Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression. Nature 373:158 – 161.  https://doi.org/10.1038/373158a0 CrossRefPubMedGoogle Scholar
  32. 32.
    Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86.  https://doi.org/10.1038/34184 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Marx N, Mach F, Sauty A et al (2000) Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164:6503–6508CrossRefGoogle Scholar
  34. 34.
    Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, Stemerman MB (2002) Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 277:34176–34181.  https://doi.org/10.1074/jbc.M203436200 CrossRefPubMedGoogle Scholar
  35. 35.
    Lee KS, Kim SR, Park SJ et al (2006) Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 118:120–127.  https://doi.org/10.1016/j.jaci.2006.03.021 CrossRefPubMedGoogle Scholar
  36. 36.
    Remels AH, Langen RC, Gosker HR et al (2009) PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab 297:E174–E183.  https://doi.org/10.1152/ajpendo.90632.2008 CrossRefPubMedGoogle Scholar
  37. 37.
    Cantó C, Pich S, Paz JC et al (2007) Neuregulins increase mitochondrial oxidative capacity and insulin sensitivity in skeletal muscle cells. Diabetes 56:2185–2193.  https://doi.org/10.2337/db06-1726 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of AnesthesiologyThe First Affiliated Hospital of Southwest Medical UniversityLuzhouChina

Personalised recommendations